Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07624578 | Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study(REIN-TEP PSMA) | withdrawn | N/A | 0 | Assistance Publique Hopitaux De MarseilleOTHER | 0 |
| Jun 3, 2026 |
| clinicaltrials |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | withdrawn | N/A | 0 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05487859 | Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona | withdrawn | N/A | 0 | University of ArizonaOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06536244 | Impact of Perioperative Anesthetic Management on Renal Cancer Progression. | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04555603 | Axitinib Therapy Management Study | withdrawn | — | 0 | PfizerINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | withdrawn | Phase 2 | 0 | Bradley A. McGregor, MDOTHER | 0 | Sep 7, 2023 | clinicaltrials |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 22, 2023 | clinicaltrials |
| NCT03390413 | Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer(ROAST) | withdrawn | N/A | 0 | Jørgen Bjerggaard JensenOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Aug 15, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT02061605 | First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy(LTW-KIDNEY) | withdrawn | N/A | 0 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors | withdrawn | — | 0 | TScan Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01401777 | Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study | withdrawn | — | 0 | Philips HealthcareINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03540199 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma(PIVOT-RCC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | withdrawn | Phase 1 | 0 | NanOlogy, LLCINDUSTRY | 0 | Aug 4, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Loma Linda UniversityOTHER | 1 | Apr 30, 2020 | clinicaltrials |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor.(R3DP-A) | withdrawn | N/A | 0 | University Hospital, BordeauxOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01633255 | [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | withdrawn | — | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials